<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04625179</url>
  </required_header>
  <id_info>
    <org_study_id>Maxillary sinus augmentation</org_study_id>
    <nct_id>NCT04625179</nct_id>
  </id_info>
  <brief_title>Melatonin and Hyaluronic Acid in Maxillary Sinus Augmentation</brief_title>
  <official_title>Evaluation of Melatonin and Hyaluronic Acid in Maxillary Sinus Augmentation (a Randomized Controlled Clinical Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hams Hamed Abdelrahman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      melatonin proved an ability to repair bone defects and enhance osseointegration of dental&#xD;
      implants. Also, hyaluronic acid has osteopromoting properties.&#xD;
&#xD;
      the effect of melatonin and hyaluronic acid on the newly formed bone in maxillary sinus&#xD;
      augmentation was evaluated&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      16 participants with missing maxillary posterior teeth and residual alveolar ridge of at&#xD;
      least 5 mm will be equally and randomly divided into two groups.&#xD;
&#xD;
      The study group will receive melatonin and hyaluronic acid after sinus membrane elevation and&#xD;
      simultaneous implant placement while the control group will not receive any materials after&#xD;
      sinus membrane elevation and simultaneous implant placement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Actual">December 7, 2020</completion_date>
  <primary_completion_date type="Actual">December 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change Implant stability</measure>
    <time_frame>at baseline and 6 months</time_frame>
    <description>The result is presented as an ISQ value of 1-100. The acceptable stability range lies between 55-85 ISQ. The higher the ISQ, the more stable the implant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in bone density</measure>
    <time_frame>at baseline, 1 month and 6 months</time_frame>
    <description>radiographical evaluation using CBCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in vertical bone height</measure>
    <time_frame>at baseline, 1 month and 6 months</time_frame>
    <description>radiographical evaluation using CBCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in marginal bone level</measure>
    <time_frame>at baseline, 1 month and 6 months</time_frame>
    <description>radiographical evaluation using CBCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>after 1 week</time_frame>
    <description>based on a 4-point verbal descriptive scale as following: no pain, mild (recognizable but not discomforting pain that required no analgesics), moderate (discomforting but bearable pain and analgesics if used were effective in relieving pain) and severe (difficult to bear and analgesics were effective in relieving pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative swelling</measure>
    <time_frame>after 1 week</time_frame>
    <description>none (no inflammation), mild (intraoral swelling confined to the surgical field), moderate (extraoral swelling in the surgical zone) and severe (extraoral swelling spreading beyond the surgical zone).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Edentulous; Alveolar Process, Atrophy</condition>
  <arm_group>
    <arm_group_label>Melatonin and hyaluronic acid and sinus membrane elevation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>melatonin and hyaluronic acid will be placed after maxillary sinus membrane elevation and simultaneous dental implants placement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sinus membrane elevation without any materials</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>no materials will be placed after maxillary sinus membrane elevation and simultaneous dental implants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Melatonin and hyaluronic acid and sinus membrane elevation</intervention_name>
    <description>3 mg melatonin powder mixed with 0.2% hyaluronic acid gel will be placed to fill the sinus space and around the implant apex.</description>
    <arm_group_label>Melatonin and hyaluronic acid and sinus membrane elevation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sinus membrane elevation without any materials</intervention_name>
    <description>No materials will be placed at the sinus space.</description>
    <arm_group_label>sinus membrane elevation without any materials</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range will be between (30 - 50) years old.&#xD;
&#xD;
          -  Patients with missed one or more of posterior teeth with minimum residual bone height&#xD;
             5 mm&#xD;
&#xD;
          -  Adequate inter-occlusal space of at least 8 mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Maxillary sinus diseases.&#xD;
&#xD;
          -  Previous sinus surgery like the Caldwell-Luc operation.&#xD;
&#xD;
          -  History of chemotherapy or radiotherapy to maxilla.&#xD;
&#xD;
          -  Presence of Underwood's septa/severe sinus floor convolutions.&#xD;
&#xD;
          -  Systemic disease affecting bone metabolism.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus.&#xD;
&#xD;
          -  Heavy smokers.&#xD;
&#xD;
          -  Para functional habits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Dentistry, Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Hams Hamed Abdelrahman</investigator_full_name>
    <investigator_title>Assistant lecturer of DPH and Clinical statistician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

